The specter of generic rivalry has long loomed above copyright’s iconic drug, Viagra, sparking questions about the future of similar medicinal investments. While first times saw impressive returns, the patent end has allowed the door for less expensive copies, potentially reducing revenue and posing a significant hazard for shareholders pursuing